PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding With The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding With The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Parties to implement a pilot program of the Veris Cancer Care Platform
各方将实施Veris癌症护理平台的试点计划
NEW YORK, April 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (the "OSUCCC – James"), a National Cancer Institute-Designated Comprehensive Cancer Center, have executed a memorandum of understanding to implement a pilot program where cancer patients would be enrolled on the Veris Cancer Care Platform.
纽约,2024年4月30日 /PRNewswire/ — PAVMed Inc.(纳斯达克股票代码:PAVM)(“PAVMed” 或 “公司”)是一家在医疗器械、诊断和数字健康领域运营的多元化商业阶段医疗技术公司,其控股的数字健康子公司Veris Health Inc.(“Veris”)今天宣布,Veris和俄亥俄州立大学综合癌症中心——亚瑟·詹姆斯癌症医院和美国国家癌症研究所指定的综合癌症中心理查德·索洛夫研究所(“OSUCCC — James”)有执行了一项谅解备忘录,以实施一项试点计划,将癌症患者注册到Veris癌症护理平台上。
"The OSUCCC – James is one of the largest and most prestigious academic cancer centers in the nation and we couldn't be more excited to work with such a renowned institution at the forefront of cancer care during the pilot program," said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer and Veris' Executive Chairman.
PavMed董事长兼首席执行官兼Veris执行董事长利山·阿克洛格医学博士说:“OSUCCC — James是美国最大和最负盛名的癌症学术中心之一,在试点计划期间能与这样一家处于癌症治疗前沿的知名机构合作,我们感到非常兴奋。”
"Our vision is to enhance personalized cancer care through the use of cutting-edge digital health tools," said Gary K. Manning, Veris' President. "We look forward to completing a successful pilot program and to offering enhanced personalized cancer care to the thousands of patients who receive systemic cancer therapy there every year."
Veris总裁加里·曼宁说:“我们的愿景是通过使用尖端的数字健康工具来增强个性化的癌症护理。”“我们期待成功完成一项试点计划,并为每年在那里接受全身癌症治疗的数千名患者提供增强的个性化癌症护理。”
"At the OSUCCC – James, personalized, compassionate cancer care is at the core of what we do. Remote monitoring allows for the integration of expert, sub-specialized oncology care in a patient's own home, surrounded by their support system. This component of the cancer care continuum is yet another way we are engaging in the future of cancer care and is in line with our pursuit of a cancer-free world," said David Cohn, M.D., M.B.A., interim chief executive officer and chief medical officer at The James Cancer Hospital and Solove Research Institute.
“在OSUCCC — James,个性化、富有同情心的癌症护理是我们工作的核心。远程监控允许将专业、亚专业的肿瘤治疗整合到患者家中,周围环绕着他们的支持系统。癌症护理连续性的这一组成部分是我们参与癌症治疗未来的另一种方式,也符合我们对无癌世界的追求。” 詹姆斯癌症医院和索洛夫研究所临时首席执行官兼首席医学官戴维·科恩医学博士、工商管理硕士学位说。
The Veris Cancer Care Platform is a comprehensive digital cancer care platform with remote physiological data collection, symptom reporting, telehealth capability, and electronic health record integration. The platform offers enhanced personalized cancer care through the early detection of complications, reduced unplanned hospitalizations, the provision of longitudinal trends of physiological and clinical data, data-driven risk management tools, and increased patient and provider satisfaction.
Veris Cancer Care Platform 是一个全面的数字癌症护理平台,具有远程生理数据收集、症状报告、远程医疗功能和电子健康记录集成。该平台通过早期发现并发症、减少计划外住院、提供生理和临床数据的纵向趋势、数据驱动的风险管理工具以及提高患者和提供者的满意度,提供增强的个性化癌症护理。
Cancer patients enrolled on the platform receive a VerisBox of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via embedded cellular connections. A complementary patient portal enables patients to report symptoms, as well as general health and quality of life parameters, to their cancer care team through the Veris patient smartphone app. The app also allows caretakers and family members to follow along on the patient's cancer care journey. Veris is also developing an implantable physiological monitor, designed to be implanted alongside a vascular access port, which will interface with the Veris Cancer Care Platform. The implantable monitor will further enhance the clinical and commercial value of the platform by providing remote physiologic data independent of patient compliance.
在该平台上注册的癌症患者将获得Veris品牌的联网医疗保健设备VerisBox,这些设备通过嵌入式蜂窝连接将生理数据传输到基于云的临床医生门户。互补的患者门户网站使患者能够通过Veris患者智能手机应用程序向其癌症治疗团队报告症状以及总体健康和生活质量参数。该应用程序还允许看护人和家庭成员关注患者的癌症护理之旅。Veris还在开发一种可植入的生理监护仪,该监视器可与血管通路端口一起植入,该端口将与Veris癌症护理平台接口。植入式监护仪将通过提供独立于患者依从性的远程生理数据,进一步提高该平台的临床和商业价值。
Cancer centers and oncology practices interested in learning more about Veris and the Veris Platform, please visit to contact a company representative.
癌症中心和肿瘤诊所有兴趣了解有关Veris和Veris平台的更多信息,请访问联系公司代表。
About PAVmed and Veris
关于 PAVMed 和 Veris
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Veris Health Inc., is a digital health company whose lead product is a digital cancer care platform with physiologic data collection, symptom reporting and telehealth functions, designed to improve personalized cancer care through remote patient monitoring. Veris has also been developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris cancer care platform. Its other majority-owned subsidiary, Lucid Diagnostics, is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths.
PavMed Inc. 是一家多元化的商业阶段医疗技术公司,业务涉及医疗器械、诊断和数字医疗领域。其控股子公司Veris Health Inc. 是一家数字健康公司,其主要产品是具有生理数据收集、症状报告和远程医疗功能的数字癌症护理平台,旨在通过远程患者监测改善个性化癌症护理。Veris还一直在开发一种可植入的生理监测器,该监视器可与化疗端口一起植入,该端口将与Veris癌症护理平台接口。其另一家控股子公司Lucid Diagnostics是一家商业阶段的癌症预防医疗诊断公司,负责销售ESOGuard 食管 DNA 测试和 ESOCheck 食管细胞收集设备——第一个也是唯一一个广泛早期发现食道癌前病变以降低食道癌死亡风险的商业工具。
For more and for more information about PAVmed, please visit pavmed.com.
如需了解有关 PavMed 的更多信息以及更多信息,请访问 pavmed.com。
For more information about Veris Health, please visit verishealth.com.
有关 Veris Health 的更多信息,请访问 verishealth.com。
For more information about Lucid Diagnostics, please visit luciddx.com.
有关 Lucid Diagnostics 的更多信息,请访问 luciddx.com。
About The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
关于俄亥俄州立大学综合癌症中心——亚瑟·詹姆斯癌症医院和理查德·索洛夫研究所
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (the "OSUCCC – James"), is the only cancer program in the United States that features a National Cancer Institute (NCI)-designated comprehensive cancer center aligned with a nationally ranked academic health center and a freestanding cancer hospital on the campus of one of the nation's largest public universities.
俄亥俄州立大学综合癌症中心——亚瑟·詹姆斯癌症医院和理查德·索洛夫研究所(“OSUCCC — James”)是美国唯一一个以国家癌症研究所(NCI)指定的综合癌症中心为特色的癌症项目,该中心与全国排名靠前的学术健康中心和位于美国最大的公立大学之一校园内的独立癌症医院相结合。
The OSUCCC – James has been designated as an NCI Comprehensive Cancer Center since 1976. Also, it is one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer agents provided by the NCI.
自1976年以来,OSUCCC — James被指定为NCI综合癌症中心。此外,它是由NCI资助的为数不多的对NCI提供的新型抗癌药物同时进行I期和II期临床试验的中心之一。
As the cancer program's adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report for 25 years and has achieved Magnet recognition, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors, more than 1.1 million square feet and 356 inpatient beds, The James is the third-largest cancer hospital in the nation.
作为癌症项目的成人患者护理组成部分,The James是全美顶级癌症医院之一 《美国新闻与世界报道》 25 年来,已获得 Magnet 认可,这是一个组织因高质量的患者护理和专业护理实践而获得的最高荣誉。詹姆斯医院共有21层,占地超过110万平方英尺,住院床位356张,是美国第三大癌症医院。
The OSUCCC – James is a global leader in such emerging disciplines as cellular therapy and immuno-oncology. In 2017, the OSUCCC – James was among the first hospitals in the United States to offer the first cellular therapy for blood cancers, known as CAR T-cell therapy, and is playing a major role in the continuing development of this and other cellular therapies.
OSUCCC — James是细胞疗法和免疫肿瘤学等新兴学科的全球领导者。2017年,OSUCCC — James是美国首批提供第一种血液癌细胞疗法(称为CAR T细胞疗法)的医院之一,并在该疗法和其他细胞疗法的持续开发中发挥了重要作用。
To learn more about cancer treatment and clinical trials at the OSUCCC – James, visit cancer.osu.edu.
要了解有关OSUCCC的癌症治疗和临床试验的更多信息,请访问cancer.osu.edu。
Forward-Looking Statements
前瞻性陈述
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
本新闻稿包括涉及风险和不确定性的前瞻性陈述。前瞻性陈述是任何非历史事实的陈述。此类前瞻性陈述基于PavMed管理层当前的信念和预期,存在风险和不确定性,这可能导致实际业绩与前瞻性陈述有所不同。可能导致此类差异的风险和不确定性包括:PavMed普通股价格的波动;总体经济和市场状况;研发固有的不确定性,包括将PavMed的产品提交监管机构申请所需的成本和时间;监管机构是否会对PavMed的临床和临床前研究的设计和结果感到满意;PavMed的产品是否以及何时获得监管机构的批准;PavMed的市场接受度曾经的产品已获批准并商业化;PavMed根据需要筹集额外资金的能力;以及其他竞争发展。这些因素很难或不可能准确预测,其中许多是PavMed无法控制的。此外,新的风险和不确定性可能不时出现,难以预测。有关这些风险和可能影响PavMed未来运营的其他重要风险和不确定性的更多清单和描述,请参阅PavMed向美国证券交易委员会提交的最新10-K表年度报告第一部分第1A项 “风险因素”,PavMed在其最新年度报告后提交的任何10-Q表季度报告的第二部分第1A项 “风险因素” 中可能会更新相同内容。PavMed不打算或有义务公开更新或修改任何前瞻性陈述,以反映其预期或这些预期所依据的事件、条件或情况的任何变化,或者可能影响实际业绩与前瞻性陈述中包含的结果不同的可能性。
SOURCE PAVmed Inc.
来源 PavMed Inc.